The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 1989
Filed:
Jun. 16, 1986
Iris H Hall, Chapel Hill, NC (US);
Steven D Wyrick, Durham, NC (US);
James M Chapman, Jr, Columbia, SC (US);
Research Corporation, , NY (US);
Abstract
A compound having the structural formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen with the provisos that if R.sup.2, R.sup.3 and R.sup.4 are hydrogen, then R.sup.1 is not methyl, n-propyl or phenyl substituted with methyl in the ortho or para position; if R.sup.1, R.sup.2 and R.sup.3 are hydrogen then R.sup.4 is not hydrogen, methyl or methoxy; and if R.sup.1 and R.sup.2 are both n-propyl or n-butyl then R.sup.3 and R.sup.4 are not both hydrogen. These compounds demonstrate utility as hypolipidemic agents. The present invention is also directed to a process for controlling hyperlipidemia in mammals comprising treating mammals with a hyperlipidemia controlling effective amount of a compound having the above-identified structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen. Yet another aspect of the present invention is embodied in a pharmaceutical composition comprising a compound having the above structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen and a pharmaceutically acceptable carrier therefor.